PT1143942E - Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas - Google Patents

Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas

Info

Publication number
PT1143942E
PT1143942E PT00914167T PT00914167T PT1143942E PT 1143942 E PT1143942 E PT 1143942E PT 00914167 T PT00914167 T PT 00914167T PT 00914167 T PT00914167 T PT 00914167T PT 1143942 E PT1143942 E PT 1143942E
Authority
PT
Portugal
Prior art keywords
medicines
manufacture
treatment
neurodegenerative diseases
receptor ligands
Prior art date
Application number
PT00914167T
Other languages
English (en)
Inventor
Raymond Bernasconi
Uwe Otten
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1143942E publication Critical patent/PT1143942E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT00914167T 1999-03-25 2000-03-23 Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas PT1143942E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9906882.7A GB9906882D0 (en) 1999-03-25 1999-03-25 Organic compounds

Publications (1)

Publication Number Publication Date
PT1143942E true PT1143942E (pt) 2003-12-31

Family

ID=10850330

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00914167T PT1143942E (pt) 1999-03-25 2000-03-23 Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas

Country Status (10)

Country Link
US (2) US20020013257A1 (pt)
EP (1) EP1143942B1 (pt)
JP (1) JP2002540143A (pt)
AT (1) ATE246922T1 (pt)
AU (1) AU3557900A (pt)
DE (1) DE60004473T2 (pt)
ES (1) ES2204542T3 (pt)
GB (1) GB9906882D0 (pt)
PT (1) PT1143942E (pt)
WO (1) WO2000057862A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372620A2 (en) * 2001-03-15 2004-01-02 Saegis Pharmaceuticals Methods for restoring cognitive function following systemic stress
CA2566204A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
JP2012158527A (ja) * 2011-01-31 2012-08-23 Mitsubishi Gas Chemical Co Inc うつ予防

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978216A (en) * 1974-06-03 1976-08-31 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
GB8728483D0 (en) * 1987-12-04 1988-01-13 Ciba Geigy Ag Chemical compounds
GB8911017D0 (en) * 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
FR2663934B1 (fr) * 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
US5214063A (en) * 1990-06-27 1993-05-25 Adir Et Compagnie 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors
AU662404B2 (en) * 1992-05-08 1995-08-31 Novartis Ag Novel N-aralkyl- and N-heteroaralkyl-aminoalkanephosphinic acids
FR2722192A1 (fr) * 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2028497A (en) * 1996-05-30 1998-01-05 Novartis Ag Metabotropic gaba{b} receptors, receptor-specific ligands and their uses
WO1998028313A1 (en) * 1996-12-24 1998-07-02 Novartis Ag (thio)morpholine-substituted carboxylic and phosphinic acids
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
DE69827635T2 (de) * 1997-06-23 2006-02-02 Neuro Therapeutics Ltd., Toorak Gaba-c-rezeptor-antagonisten zur stimulation des erinnerungsvermögens

Also Published As

Publication number Publication date
JP2002540143A (ja) 2002-11-26
ES2204542T3 (es) 2004-05-01
EP1143942A3 (en) 2002-09-11
US20060148707A1 (en) 2006-07-06
DE60004473T2 (de) 2004-07-08
DE60004473D1 (de) 2003-09-18
WO2000057862A2 (en) 2000-10-05
WO2000057862A3 (en) 2001-08-09
AU3557900A (en) 2000-10-16
EP1143942A2 (en) 2001-10-17
GB9906882D0 (en) 1999-05-19
EP1143942B1 (en) 2003-08-13
US20020013257A1 (en) 2002-01-31
ATE246922T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
AP2002002620A0 (en) Substituted arylpyrazines
DK1176963T3 (da) Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
DK1588706T3 (da) Valsartantablet
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
DK1450811T3 (da) Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
NO995823L (no) Terapeutisk middel for ereksjonsdysfunksjon
IS8162A (is) Aðferð til að meðhöndla eða fyrirbyggja neðri þvagvegaeinkenni
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
EE04905B1 (et) Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
DE60332663D1 (de) CCR1-Rezeptor-Antagonisten zur Behandlung u.a. Demyelinisierender entzündlicher Erkrankungen
ATE323680T1 (de) 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
PT1143942E (pt) Uso de ligandos de receptores gaba para a manufactura de medicamentos para o tratamento de doencas neurodegenerativas
DK0883401T3 (da) AT1-receptorantagonist til stimulering af apoptose
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
NO20001894L (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
SE9802836L (sv) Läkemedel för behandling av schizofreni
DK0900078T3 (da) Anvendelse af benzonaphthalenderivater til fremstilling af lægemidler til behandling af sygdomme i nervesystemet
ECSP993101A (es) Metodo para el tratamiento de enfermedades neovasculares oculares
DK1040830T3 (da) Lægemiddel til neurodegenerative sygdomme
DK1135134T3 (da) Anvendelse af stimulatorer af neurotrofisk faktor til behandling af oftalmiske, neurodegenerative sygdomme